Silicon Valley Bank
July 31, 2014 by Arezu Sarvestani
The funding environment for medical device startups isn’t a pretty scene, but there is a ray of sunshine through the gloom: lack of FDA approval is no longer a deal-breaker for a big exit.
In 2013 a few medtech companies managed "big exit M&A" deals (those worth $50 million or more) without having reached the FDA’s brass ring, according to a new report from Silicon Valley Bank.
If you’re a startup medical device company looking for an angel, it pays to go west, according to a new report.
The most active angel investors for medical device, diagnostics, biotechnology and other life science companies appear to be clustering, according to a new report by Silicon Valley Bank and the Angel Resource Institute.
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Implantable Provider Group Secures a Three-Fold Increase in Their Line of Credit from Silicon Valley Bank
ATLANTA–(BUSINESS WIRE)–Implantable Provider Group (IPG), a leader in providing market based medical implant solutions that deliver tangible value to payors, manufacturers, providers and patients, has secured a three-fold increase in their line of credit arrangement with Silicon Valley Bank. Profitable since inception in 2004, IPG has grown at a 76% compounded annual rate for the past seven years, with a primary focus on large, fast-growth device intensive markets, such as cardiology, neurology, orthopedic and spine implants.